 CARMIEL, Israel and BOSTON, June 2, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthare Group Chiesi Group, today provided an update regarding the clinical development of pegunigalsidase alfa PRX102 for the proposed treatment of Fabry disease. 